Close

UPDATE: JPMorgan Downgrades Amarin Corporation (AMRN) to Underweight

Go back to UPDATE: JPMorgan Downgrades Amarin Corporation (AMRN) to Underweight

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022 7:00 AM EDT

 Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden

Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets

Continued Progress on Go-To-Market Strategy in the US

Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022

Company to Host Conference Call Today at 8:00 a.m. ET

DUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:... More